{ }
The global Healthcare Contract Research Organization (CRO) market, valued at USD 66.2 billion in 2023, is projected to reach USD 135.7 billion by 2030, growing at a CAGR of 10.8%. Key drivers include increasing outsourcing demand and a focus on personalized medicine, while challenges involve regulatory compliance and operational costs. The report covers market segmentation by product type, application, and region, providing insights into trends, growth drivers, and competitive landscape.
WuXi ATU will manufacture and test WU-NK-101, a groundbreaking cell therapy for cancer patients. The global clinical trials market is projected to reach $93.42 billion by 2032, driven by rising pharmaceutical R&D investments and an increasing number of trials, particularly in Phase III and autoimmune indications. Major players include IQVIA, LabCorp, and WuXi AppTec, focusing on innovative therapies and AI integration to enhance drug discovery efficiency.
UBS analyst Chen Chen upgraded Wuxi Apptec from Neutral to Buy, raising the price target from HK$40.10 to HK$70.40, citing signs of recovery in the CRO sector and improved revenue growth. Despite the company's Q3 2024 results missing estimates, the outlook is bolstered by potential economic stimulus in China and recent Federal Reserve rate cuts. UBS has also revised its revenue, margin, and EPS estimates for 2025-2028, reflecting a more favorable risk-return balance for investors.
WuXi AppTec Co. reported third-quarter revenue of 10.5 billion yuan ($1.47 billion), a 2% decline but surpassing analysts' expectations of 10 billion yuan. Revenue from US clients reached 17.6 billion yuan in the first nine months of the year, marking a 7.6% increase year-over-year, excluding Covid-19 projects.
Trending
Subcategory:
Countries:
Companies:
Currencies:
People:

Machinary offers a groundbreaking, modular, and customizable solution that provides advanced financial news and statistical analysis. Our platform goes beyond traditional quantitative analysis, offering users a comprehensive understanding of real-time market dynamics, event detection, and risk analysis.

Address

Waitlist

We’re granting exclusive early access to the first 500 users from december 20.

© 2024 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings

Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.